Neuronetics, Inc. (NASDAQ: STIM) is a commercial-stage medical technology company focused on the development and delivery of non-invasive therapies for the treatment of neuropsychiatric disorders. Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics pioneered the use of transcranial magnetic stimulation (TMS) as an alternative to pharmacotherapy for patients suffering from major depressive disorder (MDD). The company’s flagship product, the NeuroStar Advanced Therapy System, has received clearances from the U.S. Food and Drug Administration and has been adopted by healthcare providers seeking to expand access to evidence-based depression treatments.
The NeuroStar Advanced Therapy System delivers targeted, FDA-cleared TMS pulses to regions of the brain implicated in mood regulation, providing an outpatient treatment option for patients who have not responded adequately to at least one antidepressant. Over two decades of clinical research, including more than 200 peer-reviewed publications, have demonstrated NeuroStar’s safety and efficacy in alleviating symptoms of MDD. The company also offers extensive training programs and ongoing clinical support to physicians and clinical staff, ensuring proper protocol adherence and patient management throughout the treatment course.
Neuronetics markets its products primarily in the United States through a dedicated, direct sales force and service network. In addition, the company has established partnerships with distributors and healthcare organizations in select international markets, including Europe, Asia-Pacific and Canada. These collaborations aim to expand the global reach of TMS therapy and foster local education initiatives for mental health professionals. Neuronetics continues to explore opportunities for new indications and markets, leveraging its proprietary TMS platform to address unmet needs in neuropsychiatry.
Under the leadership of President and Chief Executive Officer Sunil Bhonsle, Neuronetics is committed to advancing patient care through innovation in neuromodulation. The company’s executive team brings together expertise in medical device commercialization, neuroscience research and clinical operations. By combining rigorous scientific validation with focused market development, Neuronetics seeks to transform the standard of care for patients with treatment-resistant depression and pave the way for broader applications of TMS technology.
AI Generated. May Contain Errors.